These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38520643)

  • 1. Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
    Zarbin MA; MacCumber MW; Karcher H; Adiguzel E; Mayhook A; LaPrise A; Bilano VL; Igwe F; Ip MS; Wykoff CC
    Ophthalmol Ther; 2024 May; 13(5):1357-1368. PubMed ID: 38520643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
    Zubricky R; McCoy J; Donkor R; Miller DG; Sonbolian N; Heaney A; Bilano V; Karcher H; Coney JM
    Ophthalmol Ther; 2023 Oct; 12(5):2397-2408. PubMed ID: 37310683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
    Coney JM; Zubricky R; Sinha SB; Sonbolian N; Zhou L; Hull TP; Lewis SA; Miller DG; Novak MA; Pendergast SD; Pham H; Platt SM; Rao LJ; Schartman JP; Singerman LJ; Donkor R; Fink M; McCoy J; Karcher H
    Int J Retina Vitreous; 2023 Feb; 9(1):8. PubMed ID: 36726178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
    Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
    Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.
    Wykoff CC; Matsumoto H; Barakat MR; Karcher H; Lozama A; Mayhook A; Oshagbemi OA; Zorina O; Hassan TS; Khanani AM; Heier JS
    Retina; 2023 Jul; 43(7):1051-1063. PubMed ID: 36893438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Aug; 130(8):795-803. PubMed ID: 36990322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.
    Khoramnia R; Figueroa MS; Hattenbach LO; Pavesio CE; Anderesi M; Schmouder R; Chen Y; de Smet MD
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1843-1856. PubMed ID: 34932153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of brolucizumab in neovascular age-related macular degeneration: A multicentre retrospective real-world study.
    Kim DJ; Kim DG; Kwak HD; Jang JY; Ji YS; Lee SH; Lee EK; Park KH; Kim JH; Lee JS; Song Y; Kim ST; Shin MH; Kim M; Park SJ; Joo K; Sagong M; Lee CS; Woo SJ
    Acta Ophthalmol; 2024 May; ():. PubMed ID: 38706195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review.
    Giunta M; Gauvin Meunier LP; Nixon D; Steeves J; Noble J
    Clin Ophthalmol; 2022; 16():2885-2894. PubMed ID: 36065355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic.
    Stepanov A; Studnicka J; Veith M; Nemec P; Vyslouzilova D; Koubek M; Nemcansky J
    Eur J Ophthalmol; 2022 Oct; ():11206721221132619. PubMed ID: 36254407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
    Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
    Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.